There is a need to enhance the clinicians’ ability to diagnose Parkinson’s Disease and Atypical PD, especially in early stages.
This biomarker test can detect α-Synuclein with 87% sensitivity, 97% specificity, and 93.9% accuracy.
Most physicians are comfortable making the clinical diagnosis of PD; however, there is still a significant amount of patients who are not easily differentiated from other movement disorders.
There is a biomarker test that can help confirm PD or Atypical PD. SYNTap provides highly sensitive and specific detection of α-Synuclein aggregates and has received FDA Breakthrough product designation for use to support diagnosis of Parkinson’s Disease.
Download the SYNTap Test Specification Sheet for details.